Sentences with word «bevacizumab»

«The FDA recently approved the use of bevacizumab as it completely changed clinical practice,» Poveda added.

«For the first time, we were able to demonstrate, in surgically resected metastases, that treatment with bevacizumab in combination with chemotherapy before metastasectomy also changes the clinical significance of the growth factors as potential biomarkers,» explains Stefan Stremitzer, one of the lead investigators from MedUni Vienna's Department of Surgery.

This is very different mechanism of action than other agents that also effect angiogenesis by inhibiting vascular endothelial growth factor (VEGF) such as bevacizumab (Avastin; Genentech).

«There has been a great deal of debate about the effectiveness of bevacizumab in treating patients with glioblastoma,» says lead author Derek Johnson, M.D., a neuro - oncologist at Mayo Clinic Cancer Center.

Results of EORTC trial 26101 presented at The 20th Annual Scientific Meeting and Education Day of the Society for Neuro - Oncology showed that bevacizumab treatment in patients with progressive glioblastoma, despite prolonged progression - free survival, does not confer a survival advantage.

Treatment with the monoclonal antibody bevacizumab, which blockades VEGF - A, inhibits this vascular growth in metastasized colorectal cancer.

Patients with age - related macular degeneration who received seven or more eye injections of the drug bevacizumab annually had a higher risk of having glaucoma surgery, according to a study published online by JAMA Ophthalmology.

For each case, 10 controls were identified; the number of intravitreous bevacizumab injections received per year was determined for both cases and controls.

Commenting on NICE's recommendation on bevacizumab (Avastin), Dr Emma Pennery, Clinical Director at Breast Cancer Care said.

Brennan D. Eadie, M.D., Ph.D., of the University of British Columbia, Vancouver, and colleagues conducted a study that included patients who had received intravitreous bevacizumab injections for exudative age - related macular degeneration.

They are currently treated with non-platinum chemotherapy, single - agents, with or without addition of the blood vessel inhibitor drug called bevacizumab.

Finally, comparing lymph node metastases from rectal cancer patients who had been treated with the angiogenesis inhibitor bevacizumab with those from patients that received no antiangiogenesis therapy found no difference in blood vessel density within the metastatic nodes.

So the researchers suggested that combining bevacizumab with cisplatin and pemetrexed may offer further survival benefits as well.

For participants with more severe vision loss (20/50 or worse), aflibercept improved vision on average nearly four lines, bevacizumab about 2.5 lines, and ranibizumab almost three lines.

Both this trial, also known as GOG 213, and the previous trial, known as OCEANS and published June 10, 2012, in the Journal of Clinical Oncology, showed a longer delay in time to the next recurrence when bevacizumab is added to standard chemotherapy.

In 2014, the FDA approved bevacizumab with chemotherapies for the treatment of women with platinum - resistant, recurrent ovarian cancer.

Both arms received paclitaxel and carboplatin for six cycles and the study arm patients continued with bevacizumab maintenance.

Interestingly, however, prescription decisions at the VA varied regionally, with some centers prescribing primarily bevacizumab, others primarily ranibizumab, and others alternating between the two drugs.

Says Stremitzer: «Hence, in the event of effective blockade of VEGF - A by bevacizumab, VEGF - B could be upregulated by the metastases as an alternative growth factor and could therefore serve as a new biomarker for efficacy of the treatment.»

«Since VEGF - A and its blockade with bevacizumab also play a major role in other cancers, such as ovarian cancer and breast cancer, VEGF - B could also serve as a new predictive biomarker and a target for new drugs for these cancers as well.

Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with the often deadly brain cancer glioblastoma, researchers report in the Feb. 20 issue of the New England Journal of Medicine.

«Our study found that, at the population level, treatment strategies involving bevacizumab prolonged survival in patients with progressive glioblastoma.»

E. Albert Reece, M.D., Ph.D., M.B.A., vice president for medical affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor and dean of the University of Maryland School of Medicine, says, «Although researchers found that bevacizumab did not improve survival for patients newly diagnosed with glioblastoma, large - scale clinical studies such as this provide scientists with very valuable information and lay the groundwork for future research.

«This study provides the strongest evidence to date that bevacizumab therapy improves survival in patients with glioblastoma.»

Dr. Mehta, who chairs the RTOG's brain tumor committee, says researchers also found an increase in symptoms among patients who took bevacizumab, compared to a placebo.

Patients with HER2 - positive disease also received neoadjuvant trastuzumab and lapatinib, two HER2 - targeted therapies, while patients with triple - negative disease also received neoadjuvant bevacizumab.

In eyes with decreased vision from DME, treatment costs of aflibercept and ranibizumab would need to decrease by 69 percent and 80 percent, respectively, to reach a cost - effectiveness threshold of $ 100,000 per QALY compared with bevacizumab during a 10 - year horizon.

Among a second cohort of 10 patients who got bevacizumab and dendritic cell vaccine alone (but no cyclophosphamide), only 30 percent survived to the two - year mark.

Dr. Wakelee also noted that previous work with drugs like bevacizumab and topotecan have shown similar promise to what this trial suggests with sunitinib, and little came of it.

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

BACKGROUND AND OBJECTIVE To determine outcomes of intravitreal ranibizumab (IVR)(Lucentis; Genentech, South San Francisco, CA) versus bevacizumab (IVB)(Avastin; Genentech, South San Francisco, CA)

Researchers analyzed data on 5,607 adult patients from the National Cancer Institute (NCI) Surveillance, Epidemiology and End Results (SEER) database before and after the conditional approval of bevacizumab for the treatment of glioblastoma in 2009.

VEGF is important for the growth of blood vessels and is the target of anti-cancer drugs such as bevacizumab, known commercially as Avastin.

The standard Medicare per - injection costs of the three anti-VEGF drugs evaluated in the study are about $ 1960 for aflibercept (Eylea), $ 1200 for ranibizumab (Lucentis) and $ 70 for bevacizumab (Avastin).

Participants on bevacizumab and ranibizumab received, on average, 10 injections, versus nine for those on aflibercept.

Adding a third drug, called bevacizumab, to the cisplatin - plus - paclitaxel cocktail further increased patient survival and is now the standard of care for patients with metastatic or recurrent carcinoma of the cervix.

Results of EORTC trial 26101 presented today at The 20th Annual Scientific Meeting and Education Day of the Society for Neuro - Oncology showed that bevacizumab treatment in patients with progressive glioblastoma, despite prolonged progression - free survival, does not confer a survival advantage.

Both the ovarian and prostate cancer trials could change clinical practice, with more women taking the drug bevacizumab (Avastin) to combat the disease in its advanced stages and more men getting radiation therapy for locally advanced prostate cancer, according to researchers who presented the findings Sunday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

The researchers found that in eyes with visual acuities (VAs) of 20/50 or worse because of DME, aflibercept produced greater average VA gains compared with bevacizumab or ranibizumab.

And that was one of the motivations for introducing a clinically - proven competitor like Mvasi (also known as bevacizumab - awwb) to the market.

The researchers turned to an anti-VEGF drug, bevacizumab, which had been approved to treat macular degeneration.

Injections of bevacizumab were able to resolve hemorrhages in seven NIV eyes without surgery, the study said.

One medication in particular is bevacizumab, a drug used to treat advanced cancers that slows the growth of new blood cells.